Integra LifeSciences Holdings Corporation (NASDAQ:IART) Director Donald E. Morel, Jr. acquired 10,000 shares of the firm’s stock in a transaction dated Friday, August 4th. The stock was bought at an average price of $49.25 per share, with a total value of $492,500.00. Following the purchase, the director now directly owns 29,612 shares in the company, valued at approximately $1,458,391. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last issued its earnings results on Wednesday, July 26th. The life sciences company reported $0.45 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.45. Integra LifeSciences Holdings Corporation had a return on equity of 16.79% and a net margin of 6.27%. The company had revenue of $282.16 million during the quarter, compared to the consensus estimate of $283.58 million. During the same quarter in the prior year, the business earned $0.40 earnings per share. The company’s revenue was up 13.2% compared to the same quarter last year.

COPYRIGHT VIOLATION WARNING: “Integra LifeSciences Holdings Corporation (NASDAQ:IART) Director Acquires $492,500.00 in Stock” was first reported by Daily Political and is the property of of Daily Political. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/08/07/integra-lifesciences-holdings-corporation-nasdaqiart-director-acquires-492500-00-in-stock.html.

IART has been the subject of several recent research reports. Jefferies Group LLC lifted their price objective on Integra LifeSciences Holdings Corporation from $50.00 to $52.00 and gave the company a “buy” rating in a research note on Friday, April 28th. Oppenheimer Holdings, Inc. set a $54.00 price objective on Integra LifeSciences Holdings Corporation and gave the company a “buy” rating in a research note on Monday, May 15th. Cantor Fitzgerald set a $65.00 price objective on Integra LifeSciences Holdings Corporation and gave the company a “buy” rating in a research note on Wednesday, July 26th. UBS AG reiterated a “buy” rating and issued a $60.00 price objective (up previously from $48.00) on shares of Integra LifeSciences Holdings Corporation in a research note on Friday, June 9th. Finally, ValuEngine cut Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, May 23rd. Five investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $52.63.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Marshall Wace North America L.P. increased its position in shares of Integra LifeSciences Holdings Corporation by 388.2% in the second quarter. Marshall Wace North America L.P. now owns 280,867 shares of the life sciences company’s stock worth $15,448,000 after buying an additional 223,333 shares in the last quarter. Jennison Associates LLC increased its position in shares of Integra LifeSciences Holdings Corporation by 12.3% in the second quarter. Jennison Associates LLC now owns 697,772 shares of the life sciences company’s stock worth $38,036,000 after buying an additional 76,548 shares in the last quarter. Turner Investments LLC increased its position in shares of Integra LifeSciences Holdings Corporation by 116.7% in the second quarter. Turner Investments LLC now owns 6,500 shares of the life sciences company’s stock worth $354,000 after buying an additional 3,500 shares in the last quarter. Chartwell Investment Partners LLC acquired a new position in shares of Integra LifeSciences Holdings Corporation during the second quarter worth approximately $2,291,000. Finally, BNP Paribas Arbitrage SA increased its position in shares of Integra LifeSciences Holdings Corporation by 72.0% in the second quarter. BNP Paribas Arbitrage SA now owns 150,981 shares of the life sciences company’s stock worth $8,230,000 after buying an additional 63,200 shares in the last quarter. 86.77% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Holdings Corporation Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Insider Buying and Selling by Quarter for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.